Linking increased airway hydration, ciliary beating, and mucociliary clearance through ENaC inhibition

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 308, Issue 1, 2015, Pages L22-L32

  Åstrand, Annika B M ^a   Hemmerling, Martin ^a   Root, James ^a   Wingren, Cecilia ^a   Pesic, Jelena ^a   Johansson, Edvin ^a   Garland, Alaina L ^b   Ghosh, Arunava ^b   Tarran, Robert ^b  

^a ASTRAZENECA R AND D   (Sweden)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Airway surface liquid; Chronic bronchitis; Chronic obstructive pulmonary disease; Ciliary beat frequency; Cystic fibrosis; Cystic fibrosis transmembrane conductance regulator; Mucociliary clearance; Tracheal potential difference

Indexed keywords

AMILORIDE; BENZAMIL; CIGARETTE SMOKE; EPITHELIAL SODIUM CHANNEL BLOCKING AGENT; EPITHELIAL SODIUM CHANNEL;

ANIMAL EXPERIMENT; ARTICLE; BRONCHUS MUCOSA; CILIARY MOTILITY; CONTROLLED STUDY; DEHYDRATION; DOSE RESPONSE; DRUG CLEARANCE; DRUG EFFICACY; DRUG POTENCY; GUINEA PIG; HUMAN; HYDRATION; IN VITRO STUDY; IN VIVO STUDY; MALE; MUCOCILIARY CLEARANCE; NONHUMAN; NORMAL HUMAN; POTENTIAL DIFFERENCE; RAT; REHYDRATION; SHORT CIRCUIT CURRENT; ACTIVE TRANSPORT; ADVERSE EFFECTS; ANIMAL; CELL CULTURE; EUKARYOTIC FLAGELLUM; FEMALE; METABOLISM; MUCUS; PATHOLOGY; RESPIRATORY TRACT MUCOSA; SHEEP; SMOKING; WISTAR RAT;

ANIMALS; BIOLOGICAL TRANSPORT, ACTIVE; CELLS, CULTURED; CILIA; EPITHELIAL SODIUM CHANNELS; FEMALE; GUINEA PIGS; HUMANS; MUCUS; RATS; RATS, WISTAR; RESPIRATORY MUCOSA; SHEEP; SMOKING;

EID: 84920273225     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.00163.2014     Document Type: Article

References (46)

1. Abraham WM. Modeling of asthma, COPD and cystic fibrosis in sheep. Pulm Pharmacol Ther 21: 743–754, 2008.
2. App EM, King M, Helfesrieder R, Kohler D, Matthys H., Acute and long-term amiloride inhalation in cystic fibrosis lung disease. A rational approach to cystic fibrosis therapy. Am Rev Respir Dis 141: 605–612, 1990.
3. Ballard ST, Spadafora D. Fluid secretion by submucosal glands of the tracheobronchial airways. Respir Physiol Neurobiol 159: 271–277, 2007.
4. Bartlett JA, Fischer AJ, McCray PB Jr. Innate immune functions of the airway epithelium. Contrib Microbiol 15: 147–163, 2008.
5. Boucher RC. Regulation of airway surface liquid volume by human airway epithelia. Pflügers Arch 445: 495–498, 2003.
6. Caldwell RA, Boucher RC, Stutts MJ. Neutrophil elastase activates near-silent epithelial Na+ channels and increases airway epithelial Na+ transport. Am J Physiol Lung Cell Mol Physiol 288: L813–L819, 2005.
7. Chmiel JF, Davis PB. State of the art: why do the lungs of patients with cystic fibrosis become infected and why can’t they clear the infection Respir Res 4: 8, 2003.
8. Clunes LA, Bridges A, Alexis N, Tarran R., In vivo versus in vitro airway surface liquid nicotine levels following cigarette smoke exposure. J Anal Toxicol 32: 201–207, 2008.
9. Clunes LA, Davies CM, Coakley RD, Aleksandrov AA, Henderson AG, Zeman KL, Worthington EN, Gentzsch M, Kreda SM, Cholon D, Bennett WD, Riordan JR, Boucher RC, Tarran R., Cigarette smoke exposure induces CFTR internalization and insolubility, leading to airway surface liquid dehydration. FASEB J 26: 533–545, 2012
10. Coote KJ, Atherton H, Young A, Sugar R, Burrows R, Smith NJ, Schlaeppi JM, Groot-Kormelink PJ, Gosling M, Danahay H. The guinea-pig tracheal potential difference as an in vivo model for the study of epithelial sodium channel function in the airways. Br J Pharmacol 155: 1025–1033, 2008.
11. Crystal RG, Randell SH, Engelhardt JF, Voynow J, Sunday ME. Airway epithelial cells: current concepts and challenges. Proc Am Thorac Soc 5: 772–777, 2008.
12. Danahay H, Jackson AD. Epithelial mucus-hypersecretion and respiratory disease. Curr Drug Targets Inflamm Allergy 4: 651–664, 2005.
13. Ganz T. Antimicrobial polypeptides. J Leukoc Biol 75: 34–38, 2004.
14. Harvey PR, Tarran R, Garoff S, Myerburg MM. Measurement of the airway surface liquid volume with simple light refraction microscopy. Am J Respir Cell Mol Biol 45: 592–599, 2011.
15. Hill AT, Campbell EJ, Hill SL, Bayley DL, Stockley RA. Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am J Med 109: 288–295, 2000.
16. Hirsh AJ. Altering airway surface liquid volume: Inhalation therapy with amiloride and hyperosmotic agents. Adv Drug Deliv Rev 54: 1445–1462, 2002.
17. Hirsh AJ, Zhang J, Zamurs A, Fleegle J, Thelin WR, Caldwell RA, Sabater JR, Abraham WM, Donowitz M, Cha B, Johnson KB, St George JA, Johnson MR, Boucher RC. Pharmacological properties of N-(3,5-diamino-6-chloropyrazine-2-carbonyl)-N=-4-[4-(2,3-dihydroxypropoxy) phenyl] butyl-guanidine methanesulfonate (552–02), a novel epithelial sodium channel blocker with potential clinical efficacy for cystic fibrosis lung disease. J Pharmacol Exp Ther 325: 77–88, 2008.
18. Hobbs CA, Da Tan C, Tarran R. Does epithelial sodium channel hyperactivity contribute to cystic fibrosis lung disease J Physiol 591: 4377–4387, 2013.
19. Hogg JC, Timens W. The pathology of chronic obstructive pulmonary disease. Annu Rev Pathol 4: 435–459, 2009.
20. Houtmeyers E, Gosselink R, Gayan-Ramirez G, Decramer M. Effects of drugs on mucus clearance. Eur Respir J 14: 452–467, 1999.
21. Jeunemaitre X, Bassilana F, Persu A, Dumont C, Champigny G, Lazdunski M, Corvol P, Barbry P. Genotype-phenotype analysis of a newly discovered family with Liddle’s syndrome. J Hypertens 15: 1091–1100, 1997.
22. Knowles MR, Boucher RC. Mucus clearance as a primary innate defense mechanism for mammalian airways. J Clin Invest 109: 571–577, 2002.
23. Lifton RP. Genetic determinants of human hypertension. Proc Natl Acad Sci USA 92: 8545–8551, 1995.
24. O’Riordan TG, Bresnik M, Phillips G, Donn KH, Zhou H, Xin Y, Ramanathan S, Johnson MR, Warnock DG. GS-5737, a novel epithelial sodium channel (ENaC) inhibitor: Results of a phase I safety and pharmacokinetic (PK) study. Pediatr Pulmonol 48: 236, 2013.
25. O’Riordan TG, Donn KH, Hodsman P, Ansede JH, Newcomb T, Lewis SA, Flitter WD, White VS, Johnson MR, Montgomery AB, Warnock DG, Boucher RC. Acute hyperkalemia associated with inhalation of a potent ENaC antagonist: Phase 1 trial of GS-9411. J Aerosol Med Pulm Drug Deliv 27: 200–208, 2014.
26. Olivier KN, Bennett WD, Hohneker KW, Zeman KL, Edwards LJ, Boucher RC, Knowles MR. Acute safety and effects on mucociliary clearance of aerosolized uridine 5=-triphosphate +/- amiloride in normal human adults. Am J Respir Crit Care Med 154: 217–223, 1996.
27. Rab A, Rowe SM, Raju SV, Bebok Z, Matalon S, Collawn JF. Cigarette smoke and CFTR: implications in the pathogenesis of COPD. Am J Physiol Lung Cell Mol Physiol 305: L530–L541, 2013.
28. Raju SV, Jackson PL, Courville CA, McNicholas CM, Sloane PA, Sabbatini G, Tidwell S, Tang LP, Liu B, Fortenberry JA, Jones CW, Boydston JA, Clancy JP, Bowen LE, Accurso FJ, Blalock JE, Dransfield MT, Rowe SM. Cigarette smoke induces systemic defects in cystic fibrosis transmembrane conductance regulator function. Am J Respir Crit Care Med 188: 1321–1330, 2013.
29. Rasmussen JE, Sheridan JT, Polk W, Davies CM, Tarran R. Cigarette smoke-induced Ca2+ release leads to cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction. J Biol Chem 289: 7671–7681, 2014.
30. Robinson M, Bye PT. Mucociliary clearance in cystic fibrosis. Pediatr Pulmonol 33: 293–306, 2002.
31. Rossier BC, Pradervand S, Schild L, Hummler E., Epithelial sodium channel and the control of sodium balance: Interaction between genetic and environmental factors. Annu Rev Physiol 64: 877–897, 2002.
32. Rubin BK, Ramirez O, Zayas JG, Finegan B, King M. Respiratory mucus from asymptomatic smokers is better hydrated and more easily cleared by mucociliary action. Am Rev Respir Dis 145: 545–547, 1992.
33. Sabater JR, Lee TA, Abraham WM. Comparative effects of salmeterol, albuterol, and ipratropium on normal and impaired mucociliary function in sheep. Chest 128: 3743–3749, 2005.
34. Stoltz DA, Meyerholz DK, Pezzulo AA, Ramachandran S, Rogan MP, Davis GJ, Hanfland RA, Wohlford-Lenane C, Dohrn CL, Bartlett JA, Nelson GA, Chang EH, Taft PJ, Ludwig PS, Estin M, Hornick EE, Launspach JL, Samuel M, Rokhlina T, Karp PH, Ostedgaard LS, Uc A, Starner TD, Horswill AR, Brogden KA, Prather RS, Richter SS, Shilyansky J, McCray PB Jr, Zabner J, Welsh MJ. Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth. Sci Transl Med 2: 29ra31, 2010.
35. Tarran R, Button B, Boucher RC. Regulation of normal and cystic fibrosis airway surface liquid volume by phasic shear stress. Annu Rev Physiol 68: 543–561, 2006.
36. Tarran R, Grubb BR, Gatzy JT, Davis CW, Boucher RC. The relative roles of passive surface forces and active ion transport in the modulation of airway surface liquid volume and composition. J Gen Physiol 118: 223–236, 2001.
37. Tarran R, Grubb BR, Parsons D, Picher M, Hirsh AJ, Davis CW, Boucher RC. The CF salt controversy: In vivo observations and therapeutic approaches. Mol Cell 8: 149–158, 2001.
38. Tarran R, Trout L, Donaldson SH, Boucher RC. Soluble mediators, not cilia, determine airway surface liquid volume in normal and cystic fibrosis superficial airway epithelia. J Gen Physiol 127: 591–604, 2006.
39. Tessier GJ, Traynor TR, Kannan MS, O’Grady SM. Mechanisms of sodium and chloride transport across equine tracheal epithelium. Am J Physiol Lung Cell Mol Physiol 259: L459–L467, 1990.
40. Tyrrell J, Tarran R. Gaining the upper hand on pulmonary drug delivery. J Pharmacovigil 2: 118, 2014.
41. Voynow JA, Rubin BK. Mucins, mucus, sputum. Chest 135: 505–512, 2009.
42. Watson MJ, Worthington EN, Clunes LA, Rasmussen JE, Jones L, Tarran R. Defective adenosine-stimulated cAMP production in cystic fibrosis airway epithelia: A novel role for CFTR in cell signaling. FASEB J 25: 2996–3003, 2011.
43. Widdicombe JH. Regulation of the depth and composition of airway surface liquid. J Anat 201: 313–318, 2002.
44. Wine JJ, Joo NS. Submucosal glands and airway defense. Proc Am Thorac Soc 1: 47–53, 2004.
45. Worthington EN, Tarran R. Methods for ASL measurements and mucus transport rates in cell cultures. Methods Mol Biol 742: 77–92, 2011.
46. Zhou Z, Treis D, Schubert SC, Harm M, Schatterny J, Hirtz S, Duerr J, Boucher RC, Mall MA. Preventive but not late amiloride therapy reduces morbidity and mortality of lung disease in betaENaC-overexpressing mice. Am J Respir Crit Care Med 178: 1245–1256, 2008.